{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-25-000002","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.452193+00:00","generated_at":"2026-05-27T04:00:28.923168+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entrada gets UK MHRA nod for Phase 1/2 trial of DMD candidate ENTR-601-44","bullets":["UK MHRA and REC authorized ELEVATE-44-201, a global Phase 1/2 MAD study of ENTR-601-44 for DMD exon 44 skipping.","Dosing every 6 weeks across three cohorts (6-18 mg/kg); Part A safety/PK/PD, Part B efficacy.","Company on track to initiate trial in Q2 2025; regulatory filings also submitted in US and EU.","Prior Phase 1 single-dose study showed ENTR-601-44 well-tolerated with no serious adverse events.","If eligible, participants may enter an open-label extension for longer-term safety/efficacy assessment."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-25-000002","json":"https://secwatch.observer/filing/0001689375-25-000002.json","markdown":"https://secwatch.observer/filing/0001689375-25-000002.md","text":"https://secwatch.observer/filing/0001689375-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/0001689375-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/trda-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:00:28.923168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}